HIV and AIDS Trial, Recruiting NCT06898203 Sponsor: Washington University School of Medicine Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT06898203
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Aim 2 of the trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with Kaposi Sarcoma confirmed through a tissue sample test
  • People who have at least 3 skin lesions from Kaposi Sarcoma
  • People who are able to understand and agree to participate in the study
  • People who are currently receiving treatment for Kaposi Sarcoma

For Aim 3 of the trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with Kaposi Sarcoma confirmed through a tissue sample test
  • People who are able to understand and agree to participate in the study
  • People who are just starting treatment for Kaposi Sarcoma for the first time

Who may not be able to join:

For Aim 2 of the trial:

  • People with Kaposi Sarcoma who are not yet starting or currently receiving treatment
  • People who are very unwell and need to be cared for in a hospital

For Aim 3 of the trial:

  • People with Kaposi Sarcoma who already took part in Aim 1 or Aim 2 of this trial
  • People who have previously received or are currently receiving treatment for Kaposi Sarcoma

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thomas Odeny, MBChB, MPH, PhD, Washington University School of Medicine

Phone: 314-273-3022

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 April 2026
Est. completion
30 November 2028

Where this trial is recruiting

Kenya Uganda

Primary endpoints

Reproducibility of KS lesion size measurements between SkinScan3D and current standard of care measurement - Aim 2 Only; Accuracy of KS lesion size measurements between SkinScan3D and current standard of care measurement - Aim 2 Only; Device usability - Aim 3 Only; Acceptability - Aim 3 Only; Appropriateness - Aim 3 Only; Feasibility - Aim 3 Only

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov